Quantinno Capital Management LP Buys 3,817 Shares of Catalent, Inc. (NYSE:CTLT)

Quantinno Capital Management LP lifted its stake in Catalent, Inc. (NYSE:CTLT) by 30.6% during the third quarter, Holdings Channel reports. The fund owned 16,290 shares of the company’s stock after acquiring an additional 3,817 shares during the quarter. Quantinno Capital Management LP’s holdings in Catalent were worth $987,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CTLT. Brooklyn Investment Group acquired a new position in Catalent during the third quarter valued at approximately $31,000. Sentry Investment Management LLC acquired a new position in Catalent in the 3rd quarter valued at $53,000. Longfellow Investment Management Co. LLC raised its holdings in Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares during the period. Thurston Springer Miller Herd & Titak Inc. lifted its position in Catalent by 57.5% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after acquiring an additional 431 shares during the last quarter. Finally, Intact Investment Management Inc. bought a new stake in Catalent during the third quarter valued at about $73,000.

Analyst Ratings Changes

A number of equities analysts have recently commented on CTLT shares. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $63.40.

Catalent Price Performance

Shares of NYSE:CTLT opened at $63.07 on Friday. The firm has a market capitalization of $11.45 billion, a PE ratio of -27.91, a PEG ratio of 2.70 and a beta of 1.15. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a 1-year low of $40.29 and a 1-year high of $63.25. The business’s 50 day moving average is $60.30 and its 200-day moving average is $58.97.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the business earned ($0.10) earnings per share. Sell-side analysts predict that Catalent, Inc. will post 0.78 earnings per share for the current year.

Insider Activity

In related news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This trade represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now owns 36,304 shares in the company, valued at approximately $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.